Betsy's Note: Patient-reported outcomes capture what traditional safety and efficacy endpoints cannot: how patients experience their disease and treatment in daily life. That evidence can influence access, clinical adoption, and the durability of a product’s value story.

‍

EXECUTIVE SUMMARY

Patient-reported outcomes (PROs) are among the most underused commercial assets in life sciences. They record what traditional endpoints do not measure: symptom burden, physical function, productivity, daily living, and quality of life.

These dimensions show how patients experience a therapy and help payers judge its value. That evidence can shape formulary decisions, guideline inclusion, outcomes-based contracts, and long-term brand defense.

Organizations that build PRO strategy into their evidence plans can gain a durable commercial advantage.

‍The commercial case for PRO data‍

PRO data that appears on the label supports a promotable claim for the field force. That is the obvious win.

The less obvious and more durable opportunity lies in everything PRO data can do without a label claim. Published in journals, presented at congresses, and embedded in AMCP dossiers and HTA filings, it gives payers, formulary committees, and guideline bodies evidence they can use in coverage and adoption decisions.

A clinical profile tells them the drug works. PRO data shows what that benefit means for the person taking it and why it matters to coverage, adoption, and value.

‍

Where the evidence meets the decision

For HTA filings, PRO-derived utility values feed directly into economic analyses. Published PRO data also supports the broader case for unmet need and treatment burden that HTA bodies weigh when assessing clinical relevance.

In formulary reviews, PRO evidence showing real-world patient benefit strengthens the case for preferred placement and favorable coverage terms.

After launch, the demands grow.

Outcomes-based contracts need defined endpoints, named data sources, and a way to track patients.

AMCP dossiers gain strength from patient data that extends beyond the trial population.

Formulary renewals, usually due two to three years after first listing, need long-term outcomes data. That data must begin accruing at launch, or it may not exist when renewal comes due.

Evidence plans that win access are designed alongside clinical development, with payer and HTA requirements built in from the start.

‍

How to build it

The evidence generation plan and target product profile must specify what PRO data is needed, who will use it, and how it will be collected across the product lifecycle.

PROs can become a clear source of differentiation among competing therapies.

Burden-of-illness and natural history studies, conducted during pre-IND or early development, document treatment burden from the patient's perspective: symptom frequency and severity, disruption to daily life, reasons for discontinuation, and breakdowns in the care pathway. This evidence can frame unmet need in the terms payers and guideline bodies use to assess value and treatment relevance.

Patient preference studies measure the tradeoffs patients make among efficacy, side effects, dosing convenience, route of administration, and impact on daily life. They reveal whether a product profile will differentiate in practice. Across a portfolio, they can also help leadership decide which indication to prioritize when several compete for investment.

Label-grade PRO claims raise the bar. The instrument must be validated for the target population. The study design must conform to agency guidance. The clinical meaning of the score change must be established. This work can take years and must begin in early development.

Qualitative research, including patient interviews, caregiver studies, and advisory boards, can contextualize the scores. It reveals the accumulating fatigue of a long treatment course, the workdays lost, and the coping strategies patients develop that their physicians never observe. This context helps payers interpret the numbers and understand their practical significance.

‍

COMING SOON:

Don't neglect HCPs in your evidence strategy

Access strategy tends to focus on what payers require. That focus is necessary, but it misses a critical link in the chain. Clinical guidelines are a leading source payers use to evaluate coverage decisions, and medical experts write them. Shaping the product’s place in the treatment landscape and defining the unmet need it fills requires identifying gaps in physician awareness and closing them with evidence on the same timeline as clinical development.

‍

Three questions for the evidence plan

‍What is the patient experience today, and where does it fall short?

The unmet need argument is strongest when it rests on what patients themselves report, not on what clinical data implies about their experience. Start here.

‍What will access and adoption require beyond the payer dossier?

This includes evidence for clinical guideline inclusion, data to support field teams in formulary conversations, and comparative claims that can influence prescriber choice.

‍Will a PRO play an operational role in the care pathway?

PRO tools can support open-label extensions, patient selection criteria, treatment response monitoring, and real-world evidence generation. Defining that role early shapes which instruments to use, how to collect the data, and where PROs fit into clinical practice.

‍

These decisions belong in the evidence generation plan. Building PRO strategy into the development timeline from the start is how patient-reported data becomes a lasting commercial edge.

‍‍ ---

Betsy J. Lahue is CEO of Alkemi, a life sciences consulting firm specializing in HEOR, Market Access, and Market Shaping.

Alkemi has contributed to launches representing tens of billions in global sales and partners with life sciences executives to build evidence, value, and access strategies that translate clinical innovation into real-world adoption. To discuss your program, contact us at www.alkemihealth.com/contact